Nivolumab Induced Multiple Endocrinopathies; Adrenal Insufficiency and Primary Hypothyroidism in a Patient With Stage IV Gastric Cancer - A Case Report

Introduction: Nivolumab is a revolutionary immune check point inhibitor (ICI) that changed the world of oncology. It prevents interaction of Program Death Receptor-1 (PD-1) and Program Death Ligand-1 (PD-L1) releasing a cascade of anti-tumor response. However, it has been associated with wide range...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelmasih, Randa, Abdelmaseih, Ramy, Gandhi, Rima, Faya, Marines, Vesely, Josef James Karl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Adrenal
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265748/
http://dx.doi.org/10.1210/jendso/bvab048.293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265748/
http://dx.doi.org/10.1210/jendso/bvab048.293

Ejemplares similares